Elliott P Vichinsky

List of Publications by Citations

405 papers	21,505 citations	69 h-index	139 g-index
432 ext. papers	24,159 ext. citations	5.8 avg, IF	6.49 L-index

#	Paper	IF	Citations
405	Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. *New England Journal of Medicine*, **1998**, 339, 5-11	59.2	1462
404	Pain in sickle cell disease. Rates and risk factors. *New England Journal of Medicine*, **1991**, 325, 11-6	59.2	1212
403	Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. *New England Journal of Medicine*, **1986**, 314, 1593-9	59.2	877
402	Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. *New England Journal of Medicine*, **2000**, 342, 1855-65	59.2	857
401	Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. *JAMA - Journal of the American Medical Association*, **2003**, 289, 1645-51	27.4	592
400	Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. *JAMA - Journal of the American Medical Association*, **2005**, 294, 81-90	27.4	522
399	Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. *New England Journal of Medicine*, **1990**, 322, 1617-21	59.2	447
398	Acute Chest Syndrome in Sickle Cell Disease: Clinical Presentation and Course. *Blood*, **1997**, 89, 1787-1792	22	420
397	A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. *New England Journal of Medicine*, **1993**, 328, 81-6	59.2	397
396	Sickle cell disease. *Nature Reviews Disease Primers*, **2018**, 4, 18010	51.1	373
395	Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia. *New England Journal of Medicine*, **2018**, 378, 1479-1493	59.2	347
394	Pulmonary complications of sickle cell disease. *New England Journal of Medicine*, **2008**, 359, 2254-65	59.2	322
393	Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. *Journal of Pediatrics*, **1995**, 126, 896-9	3.6	299
392	Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease. *Blood*, **2002**, 99, 3014-8	2.2	273
391	Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease?. *American Journal of Respiratory and Critical Care Medicine*, **2003**, 168, 63-9	10.2	258
390	Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. *Transfusion*, **2001**, 41, 1086-92	2.9	252
389	A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. *British Journal of Haematology*, **2007**, 136, 501-8	4.5	233

388	Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. *British Journal of Haematology*, **2006**, 135, 254-63	4.5	229
387	Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease. *Journal of Pediatrics*, **2001**, 139, 385-90	3.6	229
386	Concurrent sickle-cell anemia and alpha-thalassemia: effect on severity of anemia. *New England Journal of Medicine*, **1982**, 306, 270-4	59.2	218
385	A Phase 3 Trial of l-Glutamine in Sickle Cell Disease. *New England Journal of Medicine*, **2018**, 379, 226-235	59.2	212
384	Neuropsychologic performance in school-aged children with sickle cell disease: a report from the Cooperative Study of Sickle Cell Disease. *Journal of Pediatrics*, **2001**, 139, 391-7	3.6	203
383	A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. *New England Journal of Medicine*, **2019**, 381, 509-519	59.2	200
382	Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. *Blood*, **2000**, 96, 3369-3373	2.2	200
381	Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia. *American Journal of Medicine*, **1997**, 102, 171-7	2.4	194
380	Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia. *JAMA - Journal of the American Medical Association*, **2010**, 303, 1823-31	27.4	187
379	Stroke prevention trial in sickle cell anemia. *Contemporary Clinical Trials*, **1998**, 19, 110-29		187
378	Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. *European Journal of Haematology*, **2008**, 80, 168-76	3.8	183
377	Non-transfusion-dependent thalassemias. *Haematologica*, **2013**, 98, 833-44	6.6	179
376	Discontinuing penicillin prophylaxis in children with sickle cell anemia. Prophylactic Penicillin Study II. *Journal of Pediatrics*, **1995**, 127, 685-90	3.6	166
375	Thalassemia. *Hematology American Society of Hematology Education Program*, **2004**, 2004, 14-34	3.1	165
374	Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. *Blood*, **2000**, 96, 76-79	2.2	162
373	Bone disease in thalassemia: a frequent and still unresolved problem. *Journal of Bone and Mineral Research*, **2009**, 24, 543-57	6.3	153
372	Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease. *British Journal of Haematology*, **2006**, 135, 574-82	4.5	148
371	Gene interactions and stroke risk in children with sickle cell anemia. *Blood*, **2004**, 103, 2391-6	2.2	145

370	Changing patterns of thalassemia worldwide. *Annals of the New York Academy of Sciences*, **2005**, 1054, 18-24	6.5	144
369	Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome. *The American Journal of Pediatric Hematology/oncology*, **2000**, 22, 515-20		142
368	Stroke and conversion to high risk in children screened with transcranial Doppler ultrasound during the STOP study. *Blood*, **2004**, 103, 3689-94	2.2	134
367	Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America. *British Journal of Haematology*, **2009**, 146, 546-56	4.5	128
366	Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi-center study of iron overload. *American Journal of Hematology*, **2007**, 82, 255-65	7.1	128
365	Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. *Blood*, **2008**, 111, 402-10	2.2	128
364	Decrease of Very Late Activation Antigen-4 and CD36 on Reticulocytes in Sickle Cell Patients Treated With Hydroxyurea. *Blood*, **1997**, 89, 2554-2559	2.2	125
363	Newborn screening for hemoglobinopathies in California. *Pediatric Blood and Cancer*, **2009**, 52, 486-90	3	122
362	Pulmonary hypertension in thalassemia: association with platelet activation and hypercoagulable state. *American Journal of Hematology*, **2006**, 81, 670-5	7.1	122
361	Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. *Clinical Therapeutics*, **2007**, 29, 909-917	3.5	112
360	Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination. *Journal of Pediatrics*, **2003**, 143, 438-44	3.6	111
359	Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients. *Pediatric Blood and Cancer*, **2007**, 49, 329-32	3	110
358	Managing sickle cell disease. *BMJ, The*, **2003**, 327, 1151-5	5.9	110
357	Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia. *American Journal of Hematology*, **2005**, 80, 70-4	7.1	110
356	Heterogeneity of hemoglobin H disease in childhood. *New England Journal of Medicine*, **2011**, 364, 710-8	59.2	108
355	Current issues with blood transfusions in sickle cell disease. *Seminars in Hematology*, **2001**, 38, 14-22	4	101
354	The perioperative complication rate of orthopedic surgery in sickle cell disease: report of the National Sickle Cell Surgery Study Group. *American Journal of Hematology*, **1999**, 62, 129-38	7.1	101
353	A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. *Haematologica*, **2013**, 98, 1375-82	6.6	100

352	Clinical application of deferasirox: practical patient management. *American Journal of Hematology*, **2008**, 83, 398-402	7.1	98
351	Hemoglobin e syndromes. *Hematology American Society of Hematology Education Program*, **2007**, 2007, 79-83	3.1	96
350	Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. *British Journal of Haematology*, **2000**, 111, 498-500	4.5	95
349	Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. *British Journal of Haematology*, **2009**, 147, 752-9	4.5	94
348	Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. *Blood*, **2009**, 114, 4632-8	2.2	90
347	Hemolysis-associated pulmonary hypertension in thalassemia. *Annals of the New York Academy of Sciences*, **2005**, 1054, 481-5	6.5	90
346	Current issues with blood transfusions in sickle cell disease. *Seminars in Hematology*, **2001**, 38, 14-22	4	90
345	Changes in the epidemiology of thalassemia in North America: a new minority disease. *Pediatrics*, **2005**, 116, e818-25	7.4	87
344	Using quality improvement strategies to enhance pediatric pain assessment. *International Journal for Quality in Health Care*, **2002**, 14, 39-47	1.9	85
343	Red cell alloimmunization in a diverse population of transfused patients with thalassaemia. *British Journal of Haematology*, **2011**, 153, 121-8	4.5	84
342	Pulmonary hypertension in sickle cell disease. *New England Journal of Medicine*, **2004**, 350, 857-9	59.2	83
341	Secretory phospholipase A2 predicts impending acute chest syndrome in sickle cell disease. *Blood*, **2000**, 96, 3276-3278	2.2	80
340	Universal newborn screening for Hb H disease in California. *Genetic Testing and Molecular Biomarkers*, **2001**, 5, 93-100		76
339	Effects of a long-term transfusion regimen on sickle cell-related illnesses. *Journal of Pediatrics*, **1994**, 125, 909-11	3.6	74
338	Multicenter comparison of magnetic resonance imaging and transcranial Doppler ultrasonography in the evaluation of the central nervous system in children with sickle cell disease. *The American Journal of Pediatric Hematology/oncology*, **2000**, 22, 335-9		72
337	Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention (CME). *Transfusion*, **2014**, 54, 972-81; quiz 971	2.9	69
336	Hydroxyurea and arginine therapy: impact on nitric oxide production in sickle cell disease. *Journal of Pediatric Hematology/Oncology*, **2003**, 25, 629-34	1.2	68
335	Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study. *Journal of Pediatrics*, **2002**, 140, 225-9	3.6	68

334	A pilot study of subcutaneous decitabine in β-thalassemia intermedia. *Blood*, **2011**, 118, 2708-11	2.2	65
333	Physical therapy alone compared with core decompression and physical therapy for femoral head osteonecrosis in sickle cell disease. Results of a multicenter study at a mean of three years after treatment. *Journal of Bone and Joint Surgery - Series A*, **2006**, 88, 2573-82	5.6	65
332	Erythrocytapheresis for chronically transfused children with sickle cell disease: an effective method for maintaining a low hemoglobin S level and reducing iron overload. *Journal of Clinical Apheresis*, **1999**, 14, 122-5	3.2	65
331	Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. *Blood*, **2012**, 119, 2746-53	2.2	63
330	Distinct HLA associations by stroke subtype in children with sickle cell anemia. *Blood*, **2003**, 101, 2865-9	2.2	63
329	Quality of life in patients with thalassemia intermedia compared to thalassemia major. *Annals of the New York Academy of Sciences*, **2005**, 1054, 457-61	6.5	62
328	Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study. *Lancet Neurology, The* , **2019**, 18, 631-642	24.1	61
327	A potent oral P-selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell disease. *American Journal of Hematology*, **2012**, 87, 536-9	7.1	61
326	Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. *Haematologica*, **2008**, 93, 817-25	6.6	61
325	Core decompression in avascular necrosis of the hip in sickle-cell disease. *American Journal of Hematology*, **1996**, 52, 103-7	7.1	61
324	Growth retardation in sickle-cell disease treated by nutritional support. *Lancet, The*, **1985**, 1, 903-6	40	61
323	Newborn screening for sickle cell disease: 4 years of experience from California's newborn screening program. *Journal of Pediatric Hematology/Oncology*, **1996**, 18, 36-41	1.2	60
322	Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. *British Journal of Haematology*, **2011**, 154, 387-97	4.5	59
321	A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction. *British Journal of Haematology*, **2011**, 153, 655-63	4.5	58
320	Mycoplasma disease and acute chest syndrome in sickle cell disease. *Pediatrics*, **2003**, 112, 87-95	7.4	58
319	Central venous catheter complications in sickle cell disease. *American Journal of Hematology*, **2002**, 69, 103-8	7.1	57
318	Combined chelation therapy with deferasirox and deferoxamine in thalassemia. *Blood Cells, Molecules, and Diseases*, **2013**, 50, 99-104	2.1	55
317	Clinical manifestations of β-thalassemia. *Cold Spring Harbor Perspectives in Medicine*, **2013**, 3, a011742	5.4	55

316	Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial. *Acta Haematologica*, **2008**, 119, 133-41	2.7	54
315	Fetal haemoglobin augmentation in E/beta(0) thalassaemia: clinical and haematological outcome. *British Journal of Haematology*, **2005**, 131, 378-88	4.5	54
314	Evidence for HLA-related susceptibility for stroke in children with sickle cell disease. *Blood*, **2000**, 95, 3562-3567	2.2	54
313	Lower alloimmunization rates in pediatric sickle cell patients on chronic erythrocytapheresis compared to chronic simple transfusions. *Transfusion*, **2012**, 52, 2671-6	2.9	53
312	Bone mineral density in children with sickle cell anemia. *Pediatric Blood and Cancer*, **2006**, 47, 901-6	3	53
311	New therapies in sickle cell disease. *Lancet, The*, **2002**, 360, 629-31	40	53
310	Changing outcome of homozygous alpha-thalassemia: cautious optimism. *The American Journal of Pediatric Hematology/oncology*, **2000**, 22, 539-42		53
309	Surgery in patients with hemoglobin SC disease. Preoperative Transfusion in Sickle Cell Disease Study Group. *American Journal of Hematology*, **1998**, 57, 101-8	7.1	52
308	Alpha thalassemia major--new mutations, intrauterine management, and outcomes. *Hematology American Society of Hematology Education Program*, **2009**, 35-41	3.1	51
307	Pulmonary hypertension and NO in sickle cell. *Blood*, **2010**, 116, 852-4	2.2	51
306	Hydroxyurea in children with sickle cell disease: impact on splenic function and compliance with therapy. *Journal of Pediatric Hematology/Oncology*, **1998**, 20, 26-31	1.2	51
305	Sickle cell disease in a patient with sickle cell trait and compound heterozygosity for hemoglobin S and hemoglobin Quebec-Chori. *New England Journal of Medicine*, **1991**, 325, 1150-4	59.2	51
304	Pulmonary hypertension in thalassemia. *Annals of the New York Academy of Sciences*, **2010**, 1202, 205-13	6.5	50
303	Assessment of sickle cell pain in children and young adults using the adolescent pediatric pain tool. *Journal of Pain and Symptom Management*, **2002**, 23, 114-20	4.8	50
302	Using qualitative and quantitative strategies to evaluate knowledge and perceptions about sickle cell disease and sickle cell trait. *Journal of the National Medical Association*, **2006**, 98, 704-10	2.3	50
301	Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report. *Blood*, **2011**, 118, 3794-802	2.2	49
300	Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia. *Bone*, **2008**, 43, 162-168	4.7	49
299	Sickle cell anemia and related hemoglobinopathies. *Pediatric Clinics of North America*, **1980**, 27, 429-47	3.6	49

298	Peroxidation, vitamin E, and sickle-cell anemia. *Annals of the New York Academy of Sciences*, **1982**, 393, 323-35	6.5	48
297	Iron chelation adherence to deferoxamine and deferasirox in thalassemia. *American Journal of Hematology*, **2011**, 86, 433-6	7.1	46
296	Variability in hepatic iron concentration in percutaneous needle biopsy specimens from patients with transfusional hemosiderosis. *American Journal of Clinical Pathology*, **2005**, 123, 146-52	1.9	46
295	Complexity of alpha thalassemia: growing health problem with new approaches to screening, diagnosis, and therapy. *Annals of the New York Academy of Sciences*, **2010**, 1202, 180-7	6.5	45
294	Clinician assessment for acute chest syndrome in febrile patients with sickle cell disease: is it accurate enough?. *Annals of Emergency Medicine*, **1999**, 34, 64-9	2.1	45
293	Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia. *American Journal of Hematology*, **1999**, 62, 221-7	7.1	45
292	Chlamydia pneumoniae and acute chest syndrome in patients with sickle cell disease. *Journal of Pediatric Hematology/Oncology*, **2003**, 25, 46-55	1.2	44
291	Reproductive capacity in iron overloaded women with thalassemia major. *Blood*, **2011**, 118, 2878-81	2.2	43
290	Dose-escalation study of ICA-17043 in patients with sickle cell disease. *Pharmacotherapy*, **2006**, 26, 1557-68	3.4	43
289	Deferoxamine treatment during pregnancy: is it harmful?. *American Journal of Hematology*, **1999**, 60, 24-6	7.1	43
288	Mechanisms of plasma non-transferrin bound iron generation: insights from comparing transfused diamond blackfan anaemia with sickle cell and thalassaemia patients. *British Journal of Haematology*, **2014**, 167, 692-6	4.5	42
287	Longitudinal changes in ferritin during chronic transfusion: a report from the Stroke Prevention Trial in Sickle Cell Anemia (STOP). *Journal of Pediatric Hematology/Oncology*, **2002**, 24, 284-90	1.2	42
286	HLA type and risk of alloimmunization in sickle cell disease. *American Journal of Hematology*, **2009**, 84, 462-4	7.1	41
285	Barriers to adherence of deferoxamine usage in sickle cell disease. *Pediatric Blood and Cancer*, **2005** , 44, 500-7	3	41
284	Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. *Haematologica*, **2008**, 93, 1247-51	6.6	40
283	Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial. *British Journal of Haematology*, **2017**, 177, 620-629	4.5	39
282	Universal screening for hemoglobinopathies using high-performance liquid chromatography: clinical results of 2.2 million screens. *European Journal of Human Genetics*, **1994**, 2, 262-71	5.3	39
281	PHYSICAL THERAPY ALONE COMPARED WITH CORE DECOMPRESSION AND PHYSICAL THERAPY FOR FEMORAL HEAD OSTEONECROSIS IN SICKLE CELL DISEASE. *Journal of Bone and Joint Surgery - Series A*, **2006**, 88, 2573-2582	5.6	39

280	Non-transfusion-dependent thalassemia and thalassemia intermedia: epidemiology, complications, and management. *Current Medical Research and Opinion*, **2016**, 32, 191-204	2.5	38
279	Advances in the treatment of alpha-thalassemia. *Blood Reviews*, **2012**, 26 Suppl 1, S31-4	11.1	38
278	Serotype-specific immunoglobulin G antibody responses to pneumococcal polysaccharide vaccine in children with sickle cell anemia: effects of continued penicillin prophylaxis. *Journal of Pediatrics*, **1996**, 129, 828-35	3.6	38
277	Iron metabolism and iron chelation in sickle cell disease. *Acta Haematologica*, **2009**, 122, 174-83	2.7	37
276	Caregiving time in sickle cell disease: psychological effects in maternal caregivers. *Pediatric Blood and Cancer*, **2007**, 48, 64-71	3	37
275	Tonsillectomy, adenoidectomy, and myringotomy in sickle cell disease: perioperative morbidity. Preoperative Transfusion in Sickle Cell Disease Study Group. *Journal of Pediatric Hematology/Oncology*, **1999**, 21, 129-35	1.2	37
274	Clinical differences between children and adults with pulmonary hypertension and sickle cell disease. *British Journal of Haematology*, **2008**, 140, 104-12	4.5	36
273	Hb E/beta-thalassaemia: a common & clinically diverse disorder. *Indian Journal of Medical Research*, **2011**, 134, 522-31	2.9	36
272	Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone. *Journal of Cardiovascular Magnetic Resonance*, **2013**, 15, 38	6.9	35
271	Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension. *Haematologica*, **2013**, 98, 1359-67	6.6	35
270	A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload. *Haematologica*, **2011**, 96, 521-5	6.6	35
269	Advances in clinical research in sickle cell disease. *British Journal of Haematology*, **2008**, 141, 346-56	4.5	35
268	Bone and joint disease in sickle cell disease. *Hematology/Oncology Clinics of North America*, **2005**, 19, 929-41, viii	3.1	35
267	Phase Ib clinical trial of starch-conjugated deferoxamine (40SD02): a novel long-acting iron chelator. *British Journal of Haematology*, **2007**, 138, 374-81	4.5	34
266	Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease. *The American Journal of Pediatric Hematology/oncology*, **2000**, 22, 330-4		34
265	Detection and assessment of stroke in patients with sickle cell disease: neuropsychological functioning and magnetic resonance imaging. *Pediatric Hematology and Oncology*, **2008**, 25, 409-21	1.7	33
264	Transfusional iron burden and liver toxicity after bone marrow transplantation for acute myelogenous leukemia and hemoglobinopathies. *Pediatric Blood and Cancer*, **2008**, 50, 319-24	3	33
263	Characterization of low bone mass in young patients with thalassemia by DXA, pQCT and markers of bone turnover. *Bone*, **2011**, 48, 1305-12	4.7	32

262	Umbilical cord blood stem cells: application for the treatment of patients with hemoglobinopathies. *Journal of Pediatrics*, **1997**, 130, 695-703	3.6	32
261	Can peak systolic velocities be used for prediction of stroke in sickle cell anemia?. *Pediatric Radiology*, **2005**, 35, 66-72	2.8	32
260	Consensus document for transfusion-related iron overload. *Seminars in Hematology*, **2001**, 38, 2-4	4	32
259	Inadequate dietary intake in patients with thalassemia. *Journal of the Academy of Nutrition and Dietetics*, **2012**, 112, 980-90	3.9	31
258	Zinc supplementation improves bone density in patients with thalassemia: a double-blind, randomized, placebo-controlled trial. *American Journal of Clinical Nutrition*, **2013**, 98, 960-71	7	31
257	Correlation of abnormal intracranial vessel velocity, measured by transcranial Doppler ultrasonography, with abnormal conjunctival vessel velocity, measured by computer-assisted intravital microscopy, in sickle cell disease. *Blood*, **2001**, 97, 3401-4	2.2	31
256	Clinical evaluation of avascular necrosis in patients with sickle cell disease: Children's Hospital Oakland Hip Evaluation Scale--a modification of the Harris Hip Score. *Archives of Physical Medicine and Rehabilitation*, **2005**, 86, 1369-75	2.8	29
255	Population based surveillance in sickle cell disease: methods, findings and implications from the California registry and surveillance system in hemoglobinopathies project (RuSH). *Pediatric Blood and Cancer*, **2014**, 61, 2271-6	3	28
254	A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease. *American Journal of Hematology*, **2012**, 87, 1017-21	7.1	28
253	Iron homeostasis during transfusional iron overload in beta-thalassemia and sickle cell disease: changes in iron regulatory protein, hepcidin, and ferritin expression. *Pediatric Hematology and Oncology*, **2007**, 24, 237-43	1.7	28
252	Emergency department utilization by Californians with sickle cell disease, 2005-2014. *Pediatric Blood and Cancer*, **2017**, 64, e26390	3	27
251	Favorable outcomes after in utero transfusion in fetuses with alpha thalassemia major: a case series and review of the literature. *Prenatal Diagnosis*, **2016**, 36, 1242-1249	3.2	27
250	Severe sickle cell disease--pathophysiology and therapy. *Biology of Blood and Marrow Transplantation*, **2010**, 16, S64-7	4.7	25
249	Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea. *American Journal of Hematology*, **2013**, 88, 1068-73	7.1	24
248	Pain in thalassaemia: the effects of age on pain frequency and severity. *British Journal of Haematology*, **2013**, 160, 680-7	4.5	24
247	Inadequate erythroid response to hypoxia in cystic fibrosis. *Journal of Pediatrics*, **1984**, 105, 15-21	3.6	24
246	Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions. *Transfusion*, **2008**, 48, 1971-80	2.9	23
245	Liver transplantation in a child with sickle cell anemia. *Transplantation*, **1995**, 59, 1490-2	1.8	23

244	Vitamin C deficiency in patients with sickle cell anemia. *Journal of Pediatric Hematology/Oncology*, **1990**, 12, 262-7	1.2	23
243	Treatment of classic pantothenate kinase-associated neurodegeneration with deferiprone and intrathecal baclofen. *American Journal of Physical Medicine and Rehabilitation*, **2013**, 92, 728-33	2.6	22
242	Correction of the anemia of epidermolysis bullosa with intravenous iron and erythropoietin. *Journal of Pediatrics*, **1998**, 132, 871-3	3.6	22
241	Chronic organ failure in adult sickle cell disease. *Hematology American Society of Hematology Education Program*, **2017**, 2017, 435-439	3.1	21
240	HbE/β-thalassemia: basis of marked clinical diversity. *Hematology/Oncology Clinics of North America*, **2010**, 24, 1055-70	3.1	21
239	A novel multilocus genotyping assay to identify genetic predictors of stroke in sickle cell anaemia. *British Journal of Haematology*, **2001**, 114, 718-20	4.5	21
238	The natural history of sickle cell disease. *Current Opinion in Pediatrics*, **1998**, 10, 49-52	3.2	21
237	Emerging α-globin therapies in hemoglobinopathies: agonists, antagonists, antioxidants, and arginine. *Hematology American Society of Hematology Education Program*, **2012**, 2012, 271-275	3.1	21
236	Influence of penicillin prophylaxis on antimicrobial resistance in nasopharyngeal S. pneumoniae among children with sickle cell anemia. The Ancillary Nasopharyngeal Culture Study of Prophylactic Penicillin Study II. *The American Journal of Pediatric Hematology/oncology*, **1997**, 19, 327-33		21
235	In utero hematopoietic cell transplantation for hemoglobinopathies. *Frontiers in Pharmacology*, **2014**, 5, 278	5.6	20
234	Variability of homozygous sickle cell disease: The role of alpha and beta globin chain variation and other factors. *Blood Cells, Molecules, and Diseases*, **2018**, 70, 66-77	2.1	20
233	Pregnancy outcomes in women with thalassemia in North America and the United Kingdom. *American Journal of Hematology*, **2013**, 88, 771-3	7.1	20
232	Relationship between chronic transfusion therapy and body composition in subjects with thalassemia. *Journal of Pediatrics*, **2010**, 157, 641-7, 647.e1-2	3.6	20
231	Sickle-cell disease not identified by newborn screening because of prior transfusion. *Journal of Pediatrics*, **2000**, 136, 248-50	3.6	20
230	Acute chest syndrome and sickle cell disease. *Current Opinion in Hematology*, **1998**, 5, 89-92	3.3	20
229	Pulmonary complications. *Hematology/Oncology Clinics of North America*, **1996**, 10, 1275-87	3.1	20
228	The prevention and management of alloimmunization in sickle cell disease: the benefit of extended phenotypic matching of red blood cells. *Immunohematology*, **2019**, 28, 20-23	0.4	20
227	Validation and reliability of a disease-specific quality of life measure (the TranQol) in adults and children with thalassaemia major. *British Journal of Haematology*, **2014**, 164, 431-7	4.5	19

226	Transfusion and chelation practices in sickle cell disease: a regional perspective. *Pediatric Hematology and Oncology*, **2011**, 28, 124-33	1.7	19
225	Suggested Guidelines for the Treatment of Children with Sickle Cell Anemia. *Hematology/Oncology Clinics of North America*, **1987**, 1, 483-501	3.1	19
224	The palatability and tolerability of deferasirox taken with different beverages or foods. *Pediatric Blood and Cancer*, **2013**, 60, 1507-12	3	18
223	The role of fetal hemoglobin-enhancing agents in thalassemia. *Seminars in Hematology*, **2004**, 41, 17-22	4	18
222	Treatment of hepatitis C virus infection in thalassemia. *Annals of the New York Academy of Sciences*, **2005**, 1054, 290-9	6.5	18
221	Outcomes of preimplantation genetic diagnosis therapy in treatment of beta-thalassemia: A retrospective analysis. *Annals of the New York Academy of Sciences*, **2005**, 1054, 500-3	6.5	18
220	The mediating effects of family functioning on psychosocial outcomes in healthy siblings of children with sickle cell disease. *Pediatric Blood and Cancer*, **2011**, 57, 1055-61	3	17
219	Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia. *British Journal of Haematology*, **2015**, 169, 887-98	4.5	16
218	Fertility in transfusion-dependent thalassemia men: effects of iron burden on the reproductive axis. *American Journal of Hematology*, **2015**, 90, E190-2	7.1	16
217	Hemoglobin E-beta-thalassemia: Progress report from the International Study Group. *Annals of the New York Academy of Sciences*, **2005**, 1054, 33-9	6.5	16
216	Utility of Holter electrocardiogram in iron-overloaded hemoglobinopathies. *Annals of the New York Academy of Sciences*, **2005**, 1054, 476-80	6.5	16
215	Identifying Clinical and Research Priorities in Sickle Cell Lung Disease. An Official American Thoracic Society Workshop Report. *Annals of the American Thoracic Society*, **2019**, 16, e17-e32	4.7	15
214	Approaches to transfusion therapy and iron overload in patients with sickle cell disease: results of an international survey. *Pediatric Hematology and Oncology*, **2011**, 28, 37-42	1.7	15
213	Oral iron chelators and the treatment of iron overload in pediatric patients with chronic anemia. *Pediatrics*, **2008**, 121, 1253-6	7.4	15
212	Hydroxycarbamide-induced changes in E/beta thalassemia red blood cells. *American Journal of Hematology*, **2008**, 83, 842-5	7.1	15
211	Update of Results from the Northstar Study (HGB-204): A Phase 1/2 Study of Gene Therapy for Beta-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex-Vivo with a Lentiviral Beta AT87Q-Globin Vector (LentiGlobin BB305 Drug Product). *Blood*, **2015**, 126, 201-201	2.2	15
210	Acute Chest Syndrome in Sickle Cell Disease: Clinical Presentation and Course. *Blood*, **1997**, 89, 1787-1792	2.2	15
209	Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. *Blood*, **2000**, 96, 3369-3373	2.2	15

208	Effect of Inhaled Cannabis for Pain in Adults With Sickle Cell Disease: A Randomized Clinical Trial. *JAMA Network Open*, **2020**, 3, e2010874	10.4	15
207	Fertility and Pregnancy in Women with Transfusion-Dependent Thalassemia. *Hematology/Oncology Clinics of North America*, **2018**, 32, 297-315	3.1	14
206	Hemoglobin H-constant spring in North America: an alpha thalassemia with frequent complications. *American Journal of Hematology*, **2009**, 84, 759-61	7.1	14
205	Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: Considerations for treatment. *Annals of the New York Academy of Sciences*, **2005**, 1054, 250-6	6.5	14
204	Pancytopenia induced by hypothermia. *Journal of Pediatric Hematology/Oncology*, **2002**, 24, 681-4	1.2	14
203	Outreach strategies for Southeast Asian communities: experience, practice, and suggestions for approaching Southeast Asian immigrant and refugee communities to provide thalassemia education and trait testing. *The American Journal of Pediatric Hematology/oncology*, **2000**, 22, 588-92		14
202	Ototoxicity in hemoglobinopathy patients chelated with desferrioxamine. *Journal of Pediatric Hematology/Oncology*, **1996**, 18, 42-5	1.2	14
201	Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Haematology,the*, **2021**, 8, e323-e333	14.6	14
200	Elevated tricuspid regurgitant jet velocity in subgroups of thalassemia patients: insight into pathophysiology and the effect of splenectomy. *Annals of Hematology*, **2014**, 93, 1139-48	3	13
199	Fertility potential in thalassemia major women: current findings and future diagnostic tools. *Annals of the New York Academy of Sciences*, **2010**, 1202, 226-30	6.5	13
198	Assessment of cardiac iron by MRI susceptometry and R2* in patients with thalassemia. *Magnetic Resonance Imaging*, **2010**, 28, 363-71	3.3	13
197	Psychosocial and behavioral outcomes in children with sickle cell disease and their healthy siblings. *Journal of Behavioral Medicine*, **2008**, 31, 506-16	3.6	13
196	Deferiprone and hepatic fibrosis. *Blood*, **2003**, 101, 5089-90; author reply 5090-1	2.2	13
195	Measuring chromosome breaks in patients with thalassemia. *Annals of the New York Academy of Sciences*, **2005**, 1054, 439-44	6.5	13
194	A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia. *Annals of the New York Academy of Sciences*, **2005**, 1054, 486-91	6.5	13
193	Lentiglobin Gene Therapy for Transfusion-Dependent Thalassemia: Update from the Northstar Hgb-204 Phase 1/2 Clinical Study. *Blood*, **2016**, 128, 1175-1175	2.2	13
192	Pulmonary hypertension in hemolytic anemias. *F1000 Medicine Reports*, **2010**, 2,		13
191	Transfusion therapy: a coming-of-age treatment for patients with sickle cell disease. *The American Journal of Pediatric Hematology/oncology*, **2001**, 23, 197-202		13

190	Long-term safety and efficacy of deferasirox in young pediatric patients with transfusional hemosiderosis: Results from a 5-year observational study (ENTRUST). *Pediatric Blood and Cancer*, **2017**, 64, e26507	3	12
189	Darbepoetin alfa for the treatment of anaemia in alpha- or beta- thalassaemia intermedia syndromes. *British Journal of Haematology*, **2011**, 154, 281-4	4.5	12
188	The social impact of migration on disease. Cooley's anemia, thalassemia, and new Asian immigrants. *Annals of the New York Academy of Sciences*, **1998**, 850, 509-11	6.5	12
187	Diseases of iron metabolism. *Pediatric Clinics of North America*, **2002**, 49, 893-909	3.6	12
186	Transfusion practices and complications in thalassemia. *Transfusion*, **2018**, 58, 2826-2835	2.9	12
185	Epidemiologic and clinical characteristics of nontransfusion-dependent thalassemia in the United States. *Pediatric Blood and Cancer*, **2018**, 65, e27067	3	11
184	Renal medullary carcinoma in an adolescent with sickle cell anemia. *Pediatric Blood and Cancer*, **2014**, 61, 567	3	11
183	Pain over time and its effects on life in thalassemia. *American Journal of Hematology*, **2013**, 88, 939-43	7.1	11
182	Hematologic problems in immigrants from Southeast Asia. *Hematology/Oncology Clinics of North America*, **2004**, 18, 1405-22, x	3.1	11
181	Bone disease in beta-thalassaemia. *Lancet, The*, **1999**, 354, 881-2	40	11
180	Transfusion practice for patients with sickle cell disease. *Current Opinion in Hematology*, **1999**, 6, 432-6	3.3	11
179	Novel influenza A (H1N1) viral infection in pediatric patients with sickle-cell disease. *Pediatric Blood and Cancer*, **2011**, 56, 95-8	3	10
178	Elevated exhaled carbon monoxide concentration in hemoglobinopathies and its relation to red blood cell transfusion therapy. *Pediatric Hematology and Oncology*, **2010**, 27, 112-21	1.7	10
177	Emerging 'A' therapies in hemoglobinopathies: agonists, antagonists, antioxidants, and arginine. *Hematology American Society of Hematology Education Program*, **2012**, 2012, 271-5	3.1	10
176	Effects of red blood cell transfusion on resting energy expenditure in adolescents with sickle cell anemia. *Journal of Pediatric Gastroenterology and Nutrition*, **1999**, 29, 127-31	2.8	10
175	Education and employment status of children and adults with thalassemia in North America. *Pediatric Blood and Cancer*, **2010**, 55, 678-83	3	9
174	Preliminary report: hydroxyurea produces significant clinical response in thalassemia intermedia. *Annals of the New York Academy of Sciences*, **1998**, 850, 461-2	6.5	9
173	Application of multiplex ligation-dependent probe amplification to screen for □globin cluster deletions: detection of two novel deletions in a multi ethnic population. *Hemoglobin*, **2013**, 37, 241-56	0.6	8

172	Prevalence of HFE mutations in California newborns. *Pediatric Hematology and Oncology*, **2006**, 23, 507-16	1.7	8
171	Liver Ferritin Subunit Ratios in Neonatal Hemochromatosis. *Pediatric Hematology and Oncology*, **2003**, 20, 229-235	1.7	8
170	Novel therapeutic approaches in sickle cell disease. *Hematology American Society of Hematology Education Program*, **2002**, 2002, 10-34	3.1	8
169	Deferasirox (Exjade), the Once-Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5-Year Follow-up.. *Blood*, **2008**, 112, 1420-1420	2.2	8
168	Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. *Blood*, **2000**, 96, 76-79	2.2	8
167	Pulmonary Hypertension in Thalassemia: Association with Hemolysis, Arginine Metabolism Dysregulation, and a Hypercoagulable State. *Advances in Pulmonary Hypertension*, **2007**, 6, 31-38	0.5	8
166	Lifespan care in SCD: Whom to transition, the patients or the health care system?. *American Journal of Hematology*, **2017**, 92, 487-489	7.1	7
165	The effect of whole body vibration therapy on bone density in patients with thalassemia: a pilot study. *American Journal of Hematology*, **2012**, 87, E76-9	7.1	7
164	Chart Card: feasibility of a tool for improving emergency department care in sickle cell disease. *Journal of the National Medical Association*, **2010**, 102, 1017-23	2.3	7
163	Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1-2):1-15.]. *Hemoglobin*, **2008**, 32, 601-7	0.6	7
162	Higher Hemoglobin Levels Achieved with Voxelotor Are Associated with Lower Vaso-occlusive Crisis Incidence: 72-Week Analysis from the HOPE Study. *Blood*, **2020**, 136, 31-32	2.2	7
161	Candidate Gene Polymorphisms and Their Association with TCD Velocities in Children with Sickle Cell Disease.. *Blood*, **2007**, 110, 429-429	2.2	7
160	Hemoglobin Hakkari: an autosomal dominant form of beta thalassemia with inclusion bodies arising from de novo mutation in exon 2 of beta globin gene. *Pediatric Blood and Cancer*, **2010**, 54, 332-5	3	6
159	New therapies and approaches to transfusion in sickle cell disease in children. *Current Opinion in Pediatrics*, **1997**, 9, 41-5	3.2	6
158	Report of Proceedings: 1999 International Conference on E- Thalassemia. *The American Journal of Pediatric Hematology/oncology*, **2000**, 22, 550		6
157	Long-Term Treatment with Deferasirox (Exjade , ICL670), a Once-Daily Oral Iron Chelator, Is Effective in Patients with Transfusion-Dependent Anemias.. *Blood*, **2007**, 110, 2777-2777	2.2	6
156	Stable to improved cardiac and pulmonary function in children with high-risk sickle cell disease following haploidentical stem cell transplantation. *Bone Marrow Transplantation*, **2021**, 56, 2221-2230	4.4	6
155	Influence of sickle cell disease on susceptibility to HIV infection. *PLoS ONE*, **2020**, 15, e0218880	3.7	6

154	Increased leucocyte apoptosis in transfused thalassaemia patients. *British Journal of Haematology*, **2013**, 160, 399-403	4.5	5
153	Encephaloduroarteriosynangiosis (EDAS) in young patients with cerebrovascular complications of sickle cell disease: Single-institution experience. *Pediatric Hematology and Oncology*, **2017**, 34, 100-106	1.7	5
152	Acute Chest Syndrome in Sickle Cell Disease: Pathophysiology and Management. *Journal of Intensive Care Medicine*, **2000**, 15, 159-166	3.3	5
151	Long-Term Clinical Outcomes of Lentiglobin Gene Therapy for Transfusion-Dependent Thalassemia in the Northstar (HGB-204) Study. *Blood*, **2019**, 134, 4628-4628	2.2	5
150	Incidence of Vaso-Occlusive Crisis Does Not Increase with Achieving Higher Hemoglobin Levels on Voxelotor Treatment or after Discontinuation: Analyses of the HOPE Study. *Blood*, **2019**, 134, 2313-2313	2.2	5
149	Long-Term Efficacy and Safety of Deferasirox (Exjade , ICL670), a Once-Daily Oral Iron Chelator, in Patients with Sickle Cell Disease (SCD).. *Blood*, **2007**, 110, 3395-3395	2.2	5
148	Sickle cell anemia, thalassemia, and congenital hemolytic anemias **2016**, 126-143		5
147	Human T cell lymphotropic virus type 1 infection among U.S. thalassemia patients. *AIDS Research and Human Retroviruses*, **2013**, 29, 1006-9	1.6	4
146	Low dose, oral epsilon aminocaproic acid for renal papillary necrosis and massive hemorrhage in hemoglobin SC disease. *Pediatric Blood and Cancer*, **2010**, 54, 148-50	3	4
145	Stem Cell Transplantation for Sickle Cell Disease: Can We Reduce the Toxicity?. *Fetal and Pediatric Pathology*, **2001**, 20, 73-86		4
144	Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. *British Journal of Haematology*, **2000**, 111, 498-500	4.5	4
143	Current treatment of sickle cell disease. *Current Problems in Pediatrics*, **1980**, 10, 1-64		4
142	Collaborative Data Project [C-DATA] of the Comprehensive Sickle Cell Centers Program.. *Blood*, **2006**, 108, 1200-1200	2.2	4
141	Long-Term Efficacy and Safety with Deferasirox (Exjade , ICL670), a Once-Daily Oral Iron Chelator, in Pediatric Patients.. *Blood*, **2007**, 110, 2774-2774	2.2	4
140	Safety of Combined Chelation Therapy with Deferasirox and Deferoxamine in Transfusion-Dependent Thalassemia.. *Blood*, **2009**, 114, 2021-2021	2.2	4
139	Chelation Choices and Iron Burden Among Patients with Thalassemia in the 21st Century: a Report From the Thalassemia Clinical Research Network (TCRN) Longitudinal Cohort.. *Blood*, **2009**, 114, 4056-4056	2.2	4
138	Arginine Therapy for Vaso-Occlusive Pain Episodes in Sickle Cell Disease.. *Blood*, **2009**, 114, 573-573	2.2	4
137	Core decompression in avascular necrosis of the hip in sickle-cell disease **1996**, 52, 103		4

136	Vincristine-induced anemia in hereditary spherocytosis. *Experimental Biology and Medicine*, **2019**, 244, 850-854	3.7	3
135	Is the medical home for adult patients with sickle cell disease a reality or an illusion?. *Hemoglobin*, **2015**, 39, 130-3	0.6	3
134	Acute Chest Syndrome in Sickle Cell Disease: Pathophysiology and Management. *Journal of Intensive Care Medicine*, **2000**, 15, 159-166	3.3	3
133	Anemia associated with rheumatoid arthritis. *Journal of Pediatrics*, **1979**, 94, 678	3.6	3
132	Efficacy and Safety of Voxelotor in Adolescents and Adults with Sickle Cell Disease: HOPE Trial 72-Week Analysis. *Blood*, **2020**, 136, 19-19	2.2	3
131	The Arginine-to-Ornithine Ratio: Biomarker of Arginase Activity and Predictor of Mortality in Sickle Cell Disease.. *Blood*, **2004**, 104, 237-237	2.2	3
130	Safety and Efficacy of Peginterferon Alfa-2a and Ribavirin for Hepatitis C in Thalassemia.. *Blood*, **2006**, 108, 558-558	2.2	3
129	A Randomized Trial of the Safety and Benefit of Transfusion Vs. Standard Care In the Prevention of Sickle Cell-Related Complications In Adults: a Preliminary Report From the Phase II NHLBI Comprehensive Sickle Cell Centers (CSCC) Study of Neuropsychological Dysfunction and Neuroimaging Abnormalities In Neurologically Intact Adult Patients with Sickle Cell Disease. *Blood*,	2.2	3
128	Baseline Characteristics of Patients with Sickle Cell Disease in An Ongoing 5-Year, Prospective, Noninterventional Registry Trial. *Blood*, **2011**, 118, 1060-1060	2.2	3
127	A Randomized Phase II Study Evaluating the Efficacy and Safety of Deferasirox Versus Deferoxamine in Patients with Sickle Cell Disease (SCD): 2-Year Results Including Pharmacokinetics (PK) and Safety of Deferasirox with Concomitant Hydroxyurea Therapy. *Blood*, **2011**, 118, 1082-1082	2.2	3
126	Anemia in the Newborn Period. *Pediatric Annals*, **1979**, 8, 10-37	1.3	3
125	Survival and causes of death in 2,033 patients with non-transfusion-dependent thalassemia. *Haematologica*, **2021**, 106, 2489-2492	6.6	3
124	The perioperative complication rate of orthopedic surgery in sickle cell disease: Report of the national sickle cell surgery study group **1999**, 62, 129		3
123	Erythrocytapheresis for chronically transfused children with sickle cell disease: An effective method for maintaining a low hemoglobin S level and reducing iron overload **1999**, 14, 122		3
122	Dietary nonheme iron is equally bioavailable from ferritin or ferrous sulfate in thalassemia intermedia. *Pediatric Hematology and Oncology*, **2017**, 34, 455-467	1.7	2
121	Clinical Outcomes of Lentiglobin Gene Therapy for Transfusion-Dependent Thalassemia Following Completion of the Northstar HGB-204 Study. *Blood*, **2018**, 132, 167-167	2.2	2
120	Results from Part A of the Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization (HOPE) Trial (GBT440-031), a Placebo-Controlled Randomized Study Evaluating Voxelotor (GBT440) in Adults and Adolescents with Sickle Cell Disease. *Blood*, **2018**, 132, 505-505	2.2	2
119	Correlation of Voxelotor Exposure with Hemoglobin Response and Measures of Hemolysis in Patients from the HOPE Study. *Blood*, **2019**, 134, 1020-1020	2.2	2

118	Barriers to Deferoxamine Adherence for Adults with Sickle Cell Disease.. *Blood*, **2004**, 104, 3760-3760	2.2	2
117	Assessing Compliance to Iron Chelation Therapy in Patients with Thalassemia.. *Blood*, **2004**, 104, 3787-3787	2.2	2
116	Serum Ferritin a Predictor of Iron Overload in Patients with Thalassemia and Sickle Cell Disease?.. *Blood*, **2004**, 104, 3789-3789	2.2	2
115	Control of Oxidant-Stress and Inflammation by Iron Chelators Deferasirox (ICL670) or Deferoxamine in Thalassemia: An Ancillary Study of the Novartis CICL670A0107 Trial.. *Blood*, **2005**, 106, 3598-3598	2.2	2
114	Pulmonary Hypertension in Thalassemia Assessed by Echocardiography: A Report From Baseline Data of the Thalassemia Clinical Research Network Longitudinal Cohort Study.. *Blood*, **2009**, 114, 2016-2016	2.2	2
113	Combined Chelation Therapy with Deferasirox and Deferoxamine In Transfusion-Dependent Thalassemia. *Blood*, **2010**, 116, 4269-4269	2.2	2
112	NKTT120 Reduces iNKT Cells without Dose Limiting Toxicity in Stable Adult Sickle Cell Patients in a Phase 1 Trial. *Blood*, **2014**, 124, 2718-2718	2.2	2
111	Secretory phospholipase A2 predicts impending acute chest syndrome in sickle cell disease. *Blood*, **2000**, 96, 3276-3278	2.2	2
110	Hemoglobinopathies **2011**, 1662-1677.e1		2
109	Clinical Outcomes For Patients With Sickle Cell Disease: 24-Month Follow-Up In An Ongoing 3-Year, Prospective, Non-Interventional Registry Trial. *Blood*, **2013**, 122, 988-988	2.2	2
108	A complication risk score to evaluate clinical severity of thalassaemia syndromes. *British Journal of Haematology*, **2021**, 192, 626-633	4.5	2
107	Iron Deficiency: Implications Before Anemia. *Pediatrics in Review*, **2021**, 42, 11-20	1.1	2
106	The transfusion management of beta thalassemia in the United States. *Transfusion*, **2021**, 61, 3027-3039	2.9	2
105	Identification of three novel Hb F variants: Hb F-Hayward [G(NA1)Gly->Asp, GGT>GAT], Hb F-Chori-I [A16(A13)Gly->Asp, GGC>GAC] and Hb F-Chori-II [A29(B11)Gly->Glu, GGA>GAA]. *Hemoglobin*, **2012**, 36, 305-9	0.6	1
104	Preface to Cooley's Anemia: Ninth Symposium. *Annals of the New York Academy of Sciences*, **2010**, 1202, ix-x	6.5	1
103	Unstable hemoglobins, hemoglobins with altered oxygen affinity, and m-hemoglobins. *Pediatric Clinics of North America*, **1980**, 27, 421-8	3.6	1
102	In Utero Stem Cell Transplantation in Patients with Alpha Thalassemia Major: Interim Results of a Phase 1 Clinical Trial. *Blood*, **2020**, 136, 1-1	2.2	1
101	Mitapivat (AG-348), an Oral PK-R Activator, in Adults with Non-Transfusion Dependent Thalassemia: A Phase 2, Open-Label, Multicenter Study in Progress. *Blood*, **2019**, 134, 2249-2249	2.2	1

100	Pulmonary Hypertension in Sickle Cell Disease: A Common Complication for Both Adults and Children.. *Blood*, **2004**, 104, 1666-1666	2.2	1
99	Progression of Organ Dysfunction in Iron Overloaded Patients with Thalassemia and Sickle Cell Disease.. *Blood*, **2004**, 104, 1683-1683	2.2	1
98	Progression of Avascular Necrosis of the Hip in Sickle Cell Disease: 2 Year Follow-Up of Randomized Trial of Aggressive Physical Therapy and Hip Coring Decompression.. *Blood*, **2004**, 104, 1685-1685	2.2	1
97	An Effective Program to Resolve Ambiguous Results from State Newborn Hemoglobinopathy Screening.. *Blood*, **2004**, 104, 3563-3563	2.2	1
96	Abnormal Pulmonary Function in Adults and Children with Sickle Cell Disease.. *Blood*, **2005**, 106, 2319-2319	2.2	1
95	Oral Arginine Increases Erythrocyte Glutathione Levels in Sickle Cell Disease: Implications for Pulmonary Hypertension.. *Blood*, **2006**, 108, 1208-1208	2.2	1
94	Leukocyte Apoptosis and Inflammation in Iron-Overloaded Patients with Sickle Cell Disease or Thalassemia: A Mechanism for Increased Stroke and Disease Severity in Sickle Cell Disease.. *Blood*, **2006**, 108, 1233-1233	2.2	1
93	MRI Assessment of Pituitary Iron and Volume in Thalassemia, and Relation to Hypothalamic-Pituitary-Gonadal Axis Function (HPG): A Feasibility Study.. *Blood*, **2006**, 108, 1778-1778	2.2	1
92	The Effect of Short-Term Simvastatin On Markers of Vascular Dysfunction in Patients with Sickle Cell Disease (SCD).. *Blood*, **2009**, 114, 260-260	2.2	1
91	Long-Term Safety and Efficacy of Deferasirox (Exjade) In Transfused Patients with Sickle Cell Disease Treated for up to 5 Years. *Blood*, **2010**, 116, 845-845	2.2	1
90	Transfusion Complications in Thalassemia: A Report From the Centers for Disease Control and Prevention (CDC). *Blood*, **2011**, 118, 340-340	2.2	1
89	Sildenafil Therapy in Patients with Thalassemia and an Elevated Tricuspid Regurgitant Jet Velocity (TRV) On Doppler Echocardiography At Risk for Pulmonary Hypertension: Report From the Thalassemia Clinical Research Network. *Blood*, **2012**, 120, 1023-1023	2.2	1
88	Innate Immune Cell Expression of Pattern Recognition Receptors From Thalassemia Patients During Intensive Combination Chelation Therapy. *Blood*, **2012**, 120, 1025-1025	2.2	1
87	Quality Improvement Goals for Sickle Cell Disease Pain Management in an Urban Pediatric Emergency Department: We Can Do Better!.. *Blood*, **2012**, 120, 2101-2101	2.2	1
86	Interim Safety and Effectiveness Results From a 5-Year Observational Study of Deferasirox in Pediatric Patients Aged 2*Blood*, **2012**, 120, 2125-2125	2.2	1
85	Epidemiologic and Clinical Characteristics of Thalassemia (Thal) Intermedia (TI) in the United States. *Blood*, **2015**, 126, 3279-3279	2.2	1
84	Consensus statement for the perinatal management of patients with alpha thalassemia major. *Blood Advances*, **2021**,	7.8	1
83	Pituitary iron and factors predictive of fertility status in transfusion dependent thalassemia. *Haematologica*, **2021**, 106, 1740-1744	6.6	1

82	An update on the US adult thalassaemia population: a report from the CDC thalassaemia treatment centres. *British Journal of Haematology*, **2021**, 196, 380	4.5	1
81	Erythrocyte Glutathione Depletion Is Associated with Severity of Anemia and Pulmonary Hypertension in Patients with Sickle Cell Disease.. *Blood*, **2006**, 108, 788-788	2.2	1
80	Comparison of Clinical Outcomes Between Adult and Pediatric Patients (pts) with Sickle Cell Disease (SCD): 3-Year (y) Follow-up in a Prospective, Longitudinal, Noninterventional Registry Trial. *Blood*, **2014**, 124, 4890-4890	2.2	1
79	Impact of Immigration and Migration on Thalassemia Surveillance in California, 2004-2008. *Blood*, **2014**, 124, 4855-4855	2.2	1
78	Iron Trafficking and Distribution in Transfusional Overload: Insights From Comparing Diamond Blackfan Anemia with Sickle Cell Disease and Thalassemia. *Blood*, **2012**, 120, 995-995	2.2	1
77	Voxelotor for the treatment of sickle cell disease. *Expert Review of Hematology*, **2021**, 14, 253-262	2.8	1
76	Time to rethink haemoglobin threshold guidelines in sickle cell disease. *British Journal of Haematology*, **2021**, 195, 518-522	4.5	1
75	Random Forest Clustering Identifies Three Subgroups of β-Thalassemia with Distinct Clinical Severity. *Thalassemia Reports*, **2022**, 12, 14-23	2	1
74	Risk of mortality from anemia and iron overload in nontransfusion-dependent β-thalassemia. *American Journal of Hematology*, **2021**,	7.1	1
73	Implications for the Metabolic Fate of Oral Glutamine Supplementation within Plasma and Erythrocytes of Patients with Sickle Cell Disease: A Pharmacokinetics Study.. *Complementary Therapies in Medicine*, **2022**, 102803	3.5	0
72	Biotin-Labeled RBC Survival in Thalassemia and Impact of Treatment.. *Blood*, **2004**, 104, 3616-3616	2.2	0
71	Long-Term Efficacy and Safety of the Oral Pyruvate Kinase Activator Mitapivat in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia. *Blood*, **2021**, 138, 576-576	2.2	0
70	Liver Iron Measurement by SQUID Compared to Liver Biopsy.. *Blood*, **2006**, 108, 3826-3826	2.2	0
69	Significantly Improved Long Term Health Related Quality of Life (HRQL) and Neurocognition Following Familial Haploidentical Stem Cell Transplantation (HISCT) Utilizing CD34 Enrichment and Mononuclear (CD3) Addback in High Risk Patients with Sickle Cell Disease (SCD). *Blood*, **2018**, 132, 162-162	2.2	0
68	Development of a Severity Score System for Thalassemia Syndromes. *Blood*, **2019**, 134, 2225-2225	2.2	0
67	Evaluation of Mandible Fractures in Patients With Sickle Cell Anemia-A Nationwide Study. *Journal of Oral and Maxillofacial Surgery*, **2019**, 77, 1418-1422	1.8	
66	Response to "efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-term follow up " Haematologica 2014;99(2):e17-18. *Haematologica*, **2014**, 99, e19	6.6	
65	Safety of deferasirox in sickle cell disease patients with co-existing liver impairment □response to Sinakos et□al. *British Journal of Haematology*, **2012**, 157, 506-507	4.5	

64	Contraceptive use in the chronically ill adolescent female. *Journal of Adolescent Health Care: Official Publication of the Society for Adolescent Medicine*, **1988**, 9, 87	
63	Three Distinct Groups of Phenotype Severity in Beta-Thalassemia. *Blood*, **2020**, 136, 15-16	2.2
62	Thalassemia Disorders in the Adolescent Female **2020**, 205-216	
61	Evidence for HLA-related susceptibility for stroke in children with sickle cell disease. *Blood*, **2000**, 95, 3562-3567	2.2
60	Low Bone Mass in Thalassemia: The Thalassemia Clinical Research Network (TCRN) Experience.. *Blood*, **2004**, 104, 3613-3613	2.2
59	Pulmonary Hypertension: A Common Complication in Thalassemia.. *Blood*, **2004**, 104, 3612-3612	2.2
58	Toxic Unbound Iron and Membrane Injury in b-Thalassemia and Sickle Cell Disease: Elevated Non-Transferrin Bound Iron (NTBI) and Malondialdehyde (MDA).. *Blood*, **2004**, 104, 3608-3608	2.2
57	Quality of Life in Patients with Thalassemia.. *Blood*, **2004**, 104, 3786-3786	2.2
56	Utility of Holter Electrocardiogram Monitoring in Iron over Loaded Thalassemia and Sickle Cell Disease.. *Blood*, **2004**, 104, 3784-3784	2.2
55	The Outcomes of Preimplantation Genetic Diagnosis Therapy in Treatment of Thalassemia - a Retrospective Analysis.. *Blood*, **2004**, 104, 3783-3783	2.2
54	Pulmonary Hypertension in Thalassemia: Association with Platelet Activation and Hypercoagulable State.. *Blood*, **2004**, 104, 3618-3618	2.2
53	Increased Chromosomal Breaks in Sickle Cell Disease as Evidenced by the Presence of Micronuclei in Erythrocytes.. *Blood*, **2005**, 106, 3807-3807	2.2
52	Hospitalization Rate and Regional Differences in Comprehensive Care in Transfused Patients with Sickle Cell Disease Compared to Thalassemia: A Report from the Multi-Center Study of Iron Overload.. *Blood*, **2005**, 106, 3189-3189	2.2
51	Dysregulated Arginine Metabolism and Elevated Arginase Activity in Thalassemia.. *Blood*, **2005**, 106, 3644-3644	2.2
50	High Prevalence of Fractures and Bone Pain in Thalassemia: The Thalassemia Clinical Research Network Experience.. *Blood*, **2005**, 106, 2706-2706	2.2
49	Serum Ferritin and Liver Iron Concentration in Patients with Iron Overload.. *Blood*, **2005**, 106, 3833-3833	2.2
48	Quality of Life (QOL) in Sickle Cell Disease (SCD).. *Blood*, **2005**, 106, 1324-1324	2.2
47	Do Transfusions of Packed Red Blood Cells Decrease Renal Function in Adult Sickle Cell Patients?.. *Blood*, **2006**, 108, 3793-3793	2.2

46	Left Ventricular Dysfunction in Chronically Transused Patients with Sickle Cell Anemia and Thalassemia.. *Blood*, **2006**, 108, 3745-3745	2.2
45	Iron Overload in Acute Myelogenous Leukemia after Bone Marrow Transplantation.. *Blood*, **2006**, 108, 5336-5336	2.2
44	Bone Mineral Density in Transfusion Independent Thalassemia Patients.. *Blood*, **2006**, 108, 3353-3353	2.2
43	Neuropsychological (NP) Dysfunction and Neuroimaging Abnormalities in Neurologically Intact Adult Patients with Sickle Cell Disease (SCD).. *Blood*, **2007**, 110, 428-428	2.2
42	High Frequency of Asthma, Sepsis and Acute Chest Syndrome in Children with Sickle Cell Disease and Pulmonary Hypertension.. *Blood*, **2007**, 110, 3782-3782	2.2
41	Leukocyte Apoptosis and Mitochondrial Dysfunction in Thalassemia Patients Treated with Deferasirox or Deferoxamine.. *Blood*, **2007**, 110, 2773-2773	2.2
40	Systemic Biomarkers Show Elevated Oxidative Stress and Chronic Inflammation in Two Disorders of Neurodegeneration with Brain Iron Accumulation (NBIA). *Blood*, **2017**, 130, 943-943	2.2
39	Trends in Iron Overload over Past Two Decades: Results from the Natural History of Iron Burden Study with the SQUID Biosusceptometer. *Blood*, **2019**, 134, 961-961	2.2
38	A Pilot Adult Sickle Cell Hematology Clinic in California's Inland Empire Improves Patient Outcome. *Blood*, **2019**, 134, 3470-3470	2.2
37	Anterior Pituitary Volume in Patients with Transfusion Dependent Anemias: Volumetric Approaches and Relation to Pituitary MRI-R2. *Clinical Neuroradiology*, **2021**, 1	2.7
36	The Role of Oxidation in Diseases of the Human Erythrocyte **1990**, 34-47	
35	Pituitary Iron and Volume Are Affecting Hormones and Reproductive Potential. *Blood*, **2014**, 124, 4048-4048	2.2
34	The Effects of Glutamine Supplementation on Markers of Autophagy and Apoptosis in Peripheral Blood Mononuclear Cells from Patients with Sickle Cell Disease. *Blood*, **2015**, 126, 3412-3412	2.2
33	NKTT120 Safely Depletes iNKT Cells in Stable Adult Sickle Cell Patients in a Phase 1 Trial. *Blood*, **2015**, 126, 2178-2178	2.2
32	Iron Level and Monocyte Morphology Predict TLR4 Expression and Reactive Oxygen Species Production Which Influences Chronic Inflammation in Thalassemia. *Blood*, **2015**, 126, 950-950	2.2
31	Sickle Cell Disease: Management of Complications **2016**, 75-87	
30	Threshold Ferritin Values to Predict Control of Liver Iron Burden in Thalassemia. *Blood*, **2016**, 128, 4824-4824	2.2
29	Long-Term Therapy with Deferasirox in Young Pediatric Patients with Transfusional Hemosiderosis Completing up to 5 Years of Treatment in the Observational E.N.T.R.U.S.T. Study. *Blood*, **2016**, 128, 2470-2470	2.2

28	Episodic Patterns of High Emergency Department Utilization Among Sickle Cell Disease Patients. *Blood*, **2016**, 128, 316-316	2.2
27	Hemoglobin H-Constant Spring in North America: A Common Alpha Thalassemia with Frequent Complications.. *Blood*, **2008**, 112, 1880-1880	2.2
26	Prolonged QTc in Sickle Cell Disease: A Potential Risk Factor for Early Death?. *Blood*, **2008**, 112, 2476-2476	2.2
25	Body Composition and Its Relationship to Growth and Bone Mass in Patients with Thalassemia. *Blood*, **2008**, 112, 3890-3890	2.2
24	Increased Nucleosomal DNA Fragmentation in Leukocytes of Thalassemia Patients.. *Blood*, **2008**, 112, 1868-1868	2.2
23	Iron Overload Diminishes the Effectiveness of the Innate Immune Response in Thalassemia Major: a Possible Mechanism for Increased Infection Risk.. *Blood*, **2009**, 114, 4071-4071	2.2
22	Heightened Sulfur Amino Acid Oxidation in Plasma and Erythrocytes in Thalassemia Major.. *Blood*, **2009**, 114, 4065-4065	2.2
21	A Phase 1B Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FBS0701, a Novel Oral Iron Chelator for the Treatment of Chronic Iron Overload. *Blood*, **2010**, 116, 2057-2057	2.2
20	Emergency Room Utilization by California Sickle Cell Patients During Pediatric to Adult Care Transition. *Blood*, **2010**, 116, 254-254	2.2
19	The Palatability and Tolerability of Deferasirox (Exjade) Taken with Meals, Different Liquids, or Crushed and Added to Food. *Blood*, **2010**, 116, 5155-5155	2.2
18	A New Method of Hip Coring Decompression for the Treatment of Femoral Avascular Necrosis In Sickle Cell Disease: Perioperative Safety and Preliminary Efficacy Data. *Blood*, **2010**, 116, 264-264	2.2
17	The Effect of Thalassemia and Other RBC Hemolytic Disorders and Splenectomy on the Frequency of Pulmonary Hypertension. *Blood*, **2010**, 116, 2077-2077	2.2
16	Phenomenon of Pain In Thalassemia: A Prospective Analysis by the Thalassemia Clinical Research Network (TCRN). *Blood*, **2010**, 116, 256-256	2.2
15	A Pilot Study of Epigenetic-Differentiation Therapy with Decitabine to Treat Thalassemia Intermedia. *Blood*, **2010**, 116, 2078-2078	2.2
14	Longitudinal Follow-up From Newborn Screening Reveals Deletional Hemoglobin H Disease and Hemoglobin H Constant Spring Disease Are Distinct Thalassemia Syndromes. *Blood*, **2010**, 116, 4260-4260	2.2
13	Safety, Tolerability and Dose Response of FBS0701, a Novel Iron Chelator for Treatment of Transfusional Iron Overload: Results of a 24-Week Multicenter, International Phase 2 Study. *Blood*, **2011**, 118, 690-690	2.2
12	Effect of Short-Term Simvastatin Treatment on Endothelial Adhesion Molecules in Sickle Cell Disease: A Pilot Study. *Blood*, **2011**, 118, 1070-1070	2.2
11	Mental Health Symptoms, Quality of Life and Barriers to Accessing Health Care in Sickle Cell Disease. *Blood*, **2011**, 118, 337-337	2.2

10	Oxidative Stress and Reproductive Capacity in Iron Overload Thalassemia Major Women. *Blood*, **2011**, 118, 2155-2155	2.2
9	Evaluation of Moyamoya Disease in Sickle Cell Anemia Patients After Encephaloduroarteriosynangiosis. *Blood*, **2011**, 118, 1059-1059	2.2
8	Renal Medullary Carcinoma in an Adolescent with Homozygous Hemoglobin SS. *Blood*, **2012**, 120, 4774-4774	2.2
7	Cardiopulmonary and Laboratory Profiling of Patients with Thalassemia At Risk for Pulmonary Hypertension: Report From the Thalassemia Clinical Research Network.. *Blood*, **2012**, 120, 2122-2122	2.2
6	12-Month Follow-up for Patients with Sickle Cell Disease in an Ongoing 3-Year, Prospective, Non-Interventional Registry Trial. *Blood*, **2012**, 120, 1010-1010	2.2
5	Tricuspid Regurgitant Jet Velocity (TRV), Biomarkers of Hemolysis, and Impact of Oxygen Therapy in Children with Sickle Cell Disease (SCD) and Vaso-Occlusive Pain Episodes (VOE). *Blood*, **2012**, 120, 4752-4752	2.2
4	Inflammatory and Vitamin Bio-Markers Of Iron Trafficking and Distribution In Transfusional Overload: Insights From Comparing Diamond Blackfan Anemia With Sickle Cell Disease and Thalassemia (MCSIO PILOT Study). *Blood*, **2013**, 122, 1014-1014	2.2
3	Association Of Cardiac Iron By T2* With Innate Immune Markers In Transfusion-Dependent Thalassemia Patients Undergoing Combined Chelation Therapy. *Blood*, **2013**, 122, 3450-3450	2.2
2	Citrate Synthase Activity Is Increased In Children With Sickle Cell Disease (SCD) On Hydroxyurea (HU) Therapy. *Blood*, **2013**, 122, 4690-4690	2.2
1	Abnormal Reproductive Measures and Seminal Plasma Findings in Men With Thalassemia Major (TM) and Iron Overload. *Blood*, **2013**, 122, 4707-4707	2.2